Technology Group International

BTG International, now a subsidiary of Boston Scientific, is a specialist healthcare company focused on interventional medicine and specialty pharmaceuticals. The company's portfolio includes life-saving antidotes such as CroFab (antivenom) and DigiFab (digoxin antidote), as well as interventional oncology products like TheraSphere (Yttrium-90 glass microspheres) for liver cancer. BTG also manages a significant licensing business, notably receiving royalties from the prostate cancer drug Zytiga. Following its acquisition by Boston Scientific in 2019, BTG's interventional medicine business has been integrated into the parent company's peripheral interventions division.